Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.
Four of the ten lowest-priced Dividend Aristocrats, including Franklin Resources and Realty Income, are ready to buy with annual dividends exceeding their single share prices. Analysts forecast 15.93% to 26.49% net gains for top-ten Aristocrat Dogs by March 2026, with Federal Realty and Stanley Black & Decker leading. A market correction of 65% could make all top-yield Aristocrats fair-priced, ...
West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's va...
EXTON, Pa. , March 5, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 at 11:00 AM ET. It will also present at the KBCM Healthcare Forum on Wednesday, March 19, 2025 at 1:30 PM ET.
EXTON, Pa. , Feb. 20, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025.
The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction.
West Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales of $749 million and adjusted earnings per share of $1.82, compared to $740 million and $1.73, respectively.
West Pharmaceutical Services, Inc. (NYSE:WST ) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Se...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.